Stability Data Preparation Service for Thai FDA Registration: Cosmetics, Food Supplements and Herbal Products

Selling health and beauty products in Thailand requires registration with the Food and Drug Administration (FDA) across every product category, from cosmetics that require a Cosmetic Notification under the Cosmetics Act B.E. 2558 (2015), food supplements requiring FDA registration under the Food Act B.E. 2522 (1979), through to herbal products requiring registration under the Herbal Product Act B.E. 2562 (2019).

The most common problem manufacturers and Brand Owners encounter is document rejection because Stability Data does not meet FDA requirements. Using testing conditions other than ASEAN Zone IVb, submitting only accelerated study data without long-term data to support it, testing an insufficient number of batches, and extrapolating shelf life beyond the limits permitted under ICH Q1E — these problems delay the registration process by months, lose the product launch window, and add unnecessary documentation costs.

TIBD’s service is designed specifically for Brand Owners, OEM manufacturers, and Indie Cosmetic Startups seeking Thai FDA registration or filing Cosmetic Notifications in ASEAN countries. It covers protocol design per ICH Q1A(R2), ICH Q1E, and the ASEAN Stability Guideline under ASEAN Zone IVb conditions, together with report preparation in ACTD Module 3.2.P.8 format accepted by Thailand’s FDA and ASEAN regulatory authorities, conducted in partnership with VISBIO as an Independent Quality Assurance Verifier (IQAV) that analyzes samples using Validated Methods per ICH Q2(R1).

Thai FDA registration is the process by which a manufacturer or importer submits product qualification documents and scientific data to the Food and Drug Administration to obtain authorization to sell in Thailand. This is a legal requirement that every product category must fulfill before manufacturing, importation, or sale can proceed.

For cosmetics, registration uses the Cosmetic Notification system, where manufacturers submit information through the FDA’s e-Notification platform and must provide a Product Information File (PIF) with stability data, safety data, and supporting qualification documents. This system applies both in Thailand and across ASEAN under the ASEAN Cosmetic Directive.

For food and food supplements, registration is stricter and operates at multiple levels depending on product type. Specifically controlled foods require individual product authorization; foods with defined quality or standards must submit formulas; and general foods must register the facility and product information. Stability data is a critical requirement for food supplements and functional foods making specific health claims.

For herbal products, the Herbal Product Act B.E. 2562 (2019) requires manufacturers to submit scientific documentation covering raw material identification and quality, Marker Compound analysis, stability testing per ICH Q1A(R2), and microbiological safety data.

Stability data requirements expected by the FDA differ by product type, and contain details that Brand Owners, OEM manufacturers, and Indie Cosmetic Startups must understand before beginning a study.

For cosmetics, the FDA expects stability data referenced to ASEAN Zone IVb conditions (30°C / 75% RH for long-term study, 40°C / 75% RH for accelerated study) for a minimum of 6 months, along with microbiological data per ISO 17516 and Preservative Efficacy Test (PET) results per ISO 11930 for water-containing products. Sunscreen products must additionally include Photostability testing per ICH Q1B and SPF/PA data at various pull points.

For food supplements, requirements are stricter than for cosmetics. Stability data for the active ingredients claimed on the label, such as vitamins, minerals, plant extracts, or live microorganisms (Probiotics), is required, along with quantitative analysis by High-Performance Liquid Chromatography (HPLC), Liquid Chromatography-Mass Spectrometry (LC-MS), or other appropriate techniques. For products containing live microorganisms, Colony Forming Unit counts (CFU/g) must not fall below the level stated on the label throughout shelf life.

For herbal products, the Herbal Product Act B.E. 2562 (2019) and the Thai Herbal Pharmacopoeia (THP 2021) impose additional requirements, covering Marker Compound analysis, TLC/HPTLC Fingerprinting, heavy metal testing, pesticide residue analysis, and aflatoxin testing.

Thailand falls within the ASEAN Zone IVb climatic zone under ICH classification. Stability data submitted to the FDA must be tested under conditions consistent with this climatic zone, and data from other zones cannot be substituted.

Long-term Stability testing accepted by the FDA uses 30°C / 75% RH conditions for a minimum of 12 months for full registration. Accelerated Stability testing uses 40°C / 75% RH conditions for 6 months to support long-term data and provide preliminary shelf-life predictions. Intermediate Stability testing at 30°C / 65% RH for 12 months is used when accelerated results show significant change.

Data from Zone II conditions (25°C / 60% RH), commonly used in Europe and North America, is insufficient for Thai FDA registration. Brand Owners importing products from abroad frequently encounter this problem and must conduct additional testing under Zone IVb conditions before submitting documents.

The number of batches tested also affects document acceptance. The FDA expects data from at least 2 production batches for cosmetics and 3 batches for food supplements and herbal products making specific health claims. Single-batch testing is a common error that leads to document rejection.

The FDA permits use of 6 months of accelerated stability data combined with at least 6 months of long-term data to support a preliminary product shelf life. Extrapolation per ICH Q1E must follow strict rules.

Extrapolation may not exceed twice the actual time for which data exists, and may not exceed 12 months beyond the available data. For example, if 6 months of long-term data plus 6 months of accelerated data showing no significant change are available, a preliminary product shelf life of 12 months can be proposed. To claim a 24-month shelf life, at least 12 months of long-term data is required.

Manufacturers who need to register quickly and extend shelf life later can use an Initial Filing strategy: propose a preliminary shelf life with 6 months of long-term data, then submit additional long-term data as a Variation when 12, 18, and 24 months of data are available. This approach allows the product to enter the market sooner and the shelf life to be extended later when the data supports it.

Stability data reports submitted to the FDA use the ASEAN Common Technical Dossier (ACTD) Module 3.2.P.8 format, the same standard used across all ASEAN countries. The report must contain three main sections.

Section P.8.1 Stability Summary and Conclusion is the overall data summary section, including the Proposed Shelf Life, Storage Conditions stated on the label, and statistical assessment conclusions per ICH Q1E.

Section P.8.2 Post-approval Stability Protocol and Stability Commitment specifies the protocol to be continued after approval, covering the number of batches in the Ongoing Stability Study and the reporting frequency to the FDA.

Section P.8.3 Stability Data contains raw and analyzed data, covering general product information, formula, package size, and packaging materials, testing conditions, Specifications and Acceptance Criteria, results presented in tables and graphs, and statistical analysis.

• Brand Owners who understand these issues before beginning a study can significantly reduce the risk of document rejection.
• The most common error is using wrong testing conditions. Using Zone II instead of Zone IVb is a frequent error among importers of foreign products. Using incorrect conditions renders all data generated unusable for Thai registration.
• Errors in batch count are also common. Single-batch testing is standard practice during early development, but for a full submission the FDA expects data from 2-3 batches to confirm production process consistency.
• Extrapolation errors occur when shelf life is extrapolated beyond the limits permitted by ICH Q1E, such as proposing a 36-month shelf life from just 6 months of long-term data. This results in immediate document rejection.
• Analytical method errors arise from using methods that have not been validated per ICH Q2(R1), making the resulting data unreliable and subject to challenge.
• Errors in parameters tested occur when critical parameters are omitted, such as Microbial Limit Test for water-containing cosmetics, Marker Compound analysis for herbal products, or UV Filter Assay for sunscreens, leaving the documentation incomplete.

Cosmetic manufacturers seeking to export to ASEAN countries can use the same stability data used for Thai FDA registration to file Cosmetic Notifications under the ASEAN Cosmetic Directive (ACD).

ASEAN regulatory authorities, including BPOM in Indonesia, NPRA in Malaysia, HSA in Singapore, DAV in Vietnam, and FDA in the Philippines, all use similar Notification systems that require a Product Information File (PIF) containing stability data referenced to the ASEAN Stability Guideline under Zone IVb conditions.

The key advantage for manufacturers who test in Thailand is that Zone IVb is the most stringent climatic zone in the ASEAN region. Data tested in Thailand can be used to support registration across all ASEAN markets without retesting, significantly reducing costs and time for market expansion.

Planning the timing for stability data preparation is something Brand Owners and OEM manufacturers must account for from the product development stage. Starting stability testing concurrently with final formula development is the strategy that reduces time to market most effectively.

For products with a Thailand-only launch target, using 6 months of accelerated data combined with 6 months of long-term data for an initial registration submission, then filing additional long-term data as a Variation later, is a widely used approach.

For products targeting simultaneous domestic sale and export to ASEAN markets, TIBD recommends planning testing under Zone IVb conditions from the outset, since Zone IVb data can support registration both domestically and across ASEAN simultaneously.

For products targeting export to the European Union, Japan, or the United States, manufacturers may need to add testing under Zone II conditions for inclusion in a Cosmetic Product Safety Report (CPSR) or other documents required by the relevant regulatory authorities. TIBD designs testing programs covering both condition sets on request.

The credibility of stability data submitted to the FDA and ASEAN regulatory authorities depends on the independence of the analyst. VISBIO, acting as an Independent Quality Assurance Verifier (IQAV), analyzes samples collected at TIBD’s various pull points using Validated Methods per ICH Q2(R1) with full traceability documentation at every step and operations conducted under ISO/IEC 17025 standards.

Having a third-party IQAV certify the data gives stability data reports submitted to the FDA greater weight in consideration compared with reports analyzed by the manufacturer, reducing the risk of challenges and helping shorten the approval process.

The stability data preparation service for registration is conducted in partnership with Dr. Wuttipong Panitsettakorn, Advisor and Co-Founder, who specializes in commercial technology management for the health and beauty industry, and Ms. Mandhamon Uttamo, Advanced Formulator, with experience in preparing data and ACTD documentation for product registration in Thailand and ASEAN. Our team includes researchers specializing in Pharmaceutical Sciences, Cosmetic Science, and Regulatory Affairs, and network researchers covering microbiological assessment, safety evaluation, and interpretation of regulatory authority requirements.

Is your cosmetic, food supplement, or herbal product ready to file with the Thai FDA or to submit a Cosmetic Notification in ASEAN? If you need stability data referenced to ICH Q1A(R2), ICH Q1E, and the ASEAN Stability Guideline with reports in ACTD Module 3.2.P.8 format accepted by the FDA, Contact TIBD for a customized protocol designed for your product.